Sun. Apr 11th, 2021

Johnson & Johnson Covid Vaccine Is 66% Efficient

J&J plans to hunt emergency use authorization subsequent week.

Johnson & Johnson mentioned on Friday that its single-dose vaccine was 66 per cent efficient in stopping COVID-19 in a big world trial in opposition to a number of variants which can give well being officers one other weapon to deal with the coronavirus.

Within the trial of almost 44,000 volunteers, the extent of safety in opposition to reasonable and extreme COVID-19 various from 72 per cent in the US, to 66 per cent in Latin America and simply 57 per cent in South Africa, from the place a worrying variant has unfold.

A excessive bar has been set by two licensed vaccines from Pfizer/BioNTech and Moderna, which have been round 95 per cent efficient in stopping symptomatic sickness in pivotal trials when given in two doses.

These trials, nevertheless, have been carried out primarily in the US and earlier than new variants emerged.

J&J’s fundamental objective was the prevention of reasonable to extreme COVID-19, and the vaccine was 85 per cent efficient in stopping extreme illness and stopping hospitalization throughout all geographies and in opposition to a number of variants 28 days after immunization.

That “will doubtlessly defend lots of of thousands and thousands of individuals from severe and deadly outcomes of COVID-19,” Paul Stoffels, J&J’s chief scientific officer, mentioned in an announcement with the outcomes, which have been primarily based on 468 symptomatic instances.

J&J plans to hunt emergency use authorization from the US Meals and Drug Administration subsequent week. It has mentioned it plans to ship 1 billion doses in 2021 and can produce the vaccine in the US, Europe, South Africa and India.

Public well being officers have been relying on the J&J vaccine to extend much-needed provide and simplify the US immunization marketing campaign.

The USA has a deal to purchase 100 million doses of J&J’s vaccine and an possibility for an extra 200 million. J&J mentioned the vaccine could be prepared instantly upon emergency approval, however Stoffels declined to specify what number of doses.

“Proper now, any safety and extra vaccine is nice,” Walid Gellad, a well being coverage affiliate professor on the College of Pittsburgh mentioned.

“The “South Africa” pressure continues to be unusual within the U.S. and clearly we might need to see increased efficacy, however the secret’s not solely total efficacy however particularly efficacy in opposition to extreme illness, hospitalization, and dying,” Gellad added

Not one of the vaccine recipients within the J&J trial died from COVID-19, in contrast with 5 deaths within the placebo group, in line with the Nationwide Institutes of Well being.

The NIH mentioned there have been three deaths within the vaccine group total, however none have been decided to be from the virus. That compares with 16 deaths total within the placebo arm.


Not like the Pfizer and Moderna vaccines, J&J’s doesn’t require a second shot weeks after the primary or must be stored frozen, making it a powerful candidate to be used in elements of the world with the place transportation and chilly storage are a difficulty.


A number of research have emerged this month exhibiting {that a} South African variant has mutated in areas of the virus which are key targets of vaccines, lowering their efficacy.

“What we’re studying is there’s totally different efficacy in several elements of the world,” Stoffels instructed Reuters.

In a sub-study of 6,000 volunteers in South Africa, Stoffels mentioned, the J&J vaccine was 89 per cent efficient at stopping extreme illness. Within the South Africa portion of the trial, 95 per cent of instances have been infections with the South African variant.

“I’m overwhelmed by the truth that this vaccine protected in opposition to extreme illness even in South Africa,” mentioned Glenda Grey, the joint lead investigator of the South African vaccine trial.

Grey, who’s the chief govt of the South African Medical Analysis Council, mentioned that is by far the most effective vaccine for South Africa to battle the mutant pressure and might stop numerous hospitalisations and deaths.

A mid-stage trial of a Novovax coronavirus vaccine in South Africa additionally confirmed decrease efficacy, proving to be 60 per cent efficient amongst volunteers who did not have HIV. In a separate, late-stage trial in Britain it was 89.3 per cent efficient.

Within the J&J trial, which was carried out in eight international locations, 44 per cent of individuals have been from the US, 41 per cent from Central and South America and 15 per cent from South Africa. Barely greater than a 3rd of the volunteers have been over 60.

J&J’s vaccine makes use of a typical chilly virus to introduce coronavirus proteins into cells within the physique and set off an immune response, whereas the Pfizer/BioNTech and Moderna vaccines use a brand new know-how referred to as messenger RNA (mRNA).

The information of one other protected and efficient vaccine comes as the US has surpassed 430,000 COVID-19 deaths and with hospitals in lots of states struggling to maintain up with sufferers regardless of current declines in new infections.

(This story has not been edited by NDTV workers and is auto-generated from a syndicated feed.)

Picture Supply : –

Underneath Part 107 of the Copyright Act 1976, allowance is made for “honest use” for functions resembling criticism, remark, information reporting, instructing, scholarship, and analysis. Truthful use is a use permitted by copyright statute that may in any other case be infringing.”

By p x

Leave a Reply

Your email address will not be published. Required fields are marked *